|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
FridayCopaxone lipoatrophy far more common than reported: he risk of lipoatrophy with glatiramer acetate is greater than 60%
The risk is "substantially higher than previously reported and [is] often the sole factor prompting patients to switch to another MS [disease-modifying therapy].
Click here to read more |